Trinity Biotech to submit IND for Uni-Gold HIV test within next three months.
This article was originally published in The Gray Sheet
TRINITY BIOTECH UNI-GOLD HIV TEST INVESTIGATIONAL NEW DRUG SUBMISSION is expected within the next three months, the Dublin, Ireland-based company says. Clinical trials for the product will be conducted under FDA's new drug/biologic investigation procedures, and the company will attempt to bring the one-step HIV assay to market via a product license application (PLA) that will be reviewed by FDA's Center for Biologics Evaluation and Research. FDA is requiring Trinity to submit a PLA rather than a premarket approval application since the assay potentially could be used to screen blood, the firm explains.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.